Format

Send to

Choose Destination
Diabetes Metab. 2012 Jun;38(3):183-91. doi: 10.1016/j.diabet.2011.11.006. Epub 2012 Jan 16.

Inflammation and type 2 diabetes.

Author information

1
Department of Nutritional Sciences, University of Connecticut, 3624 Horsebarn Road, ext. U-4017, Storrs, CR 06269, USA.

Abstract

Low-grade inflammation is a common feature in subjects with type 2 diabetes (T2D). Heart disease, the metabolic syndrome and T2D all have in common the increased concentration of circulatory cytokines as a result of inflammation. Inflammatory cytokines are produced by different cell types and secreted into the circulation, where they regulate different tissues through their local, central and peripheral actions. This review focuses on C-reactive protein (CRP), a well-established marker of the development of inflammation, on tumour necrosis factor (TNF)-α, an inflammatory marker strongly associated with diabetes, and on adiponectin, a cytokine produced by adipose tissue and associated with insulin sensitivity. While it is clear from the literature that these cytokines play a major role in the development of T2D or, in the case of adiponectin, its prevention, the best strategy for favourably altering the inflammatory response is still a matter of debate.

PMID:
22252015
DOI:
10.1016/j.diabet.2011.11.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center